γδ T Cells for Cancer Immunotherapy: Unconventional Players Take the Spotlight

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Cancer immunotherapy success relies on effective leukocyte mobilization against tumors.
• Gamma delta T (γδ T) cells possess inherent cytotoxic potential and produce antitumor cytokines.
• γδ T cells offer advantages over other T cells by not being restricted to MHC-mediated antigen presentation, addressing key immunotherapy challenges.

Purpose of the Study:

• To review current approaches for engaging and expanding γδ T cells for cancer treatment, both in vivo and ex vivo.
• To discuss the balance between γδ T cell activation and exhaustion, and their potential synergy with immune checkpoint blockade.
• To explore the biological properties of Vδ1 and Vδ2 T cell subsets and advancements in genetic engineering for enhanced cancer immunotherapy.

Main Methods:

• Review of existing literature on γδ T cell biology and cancer immunotherapy.
• Analysis of endogenous and exogenous strategies for γδ T cell activation and expansion.
• Examination of genetic engineering techniques to augment γδ T cell therapeutic efficacy.

Main Results:

• γδ T cells are versatile candidates for cancer immunotherapy due to their unique properties.
• Strategies exist to harness γδ T cells via endogenous activation or exogenous adoptive cell therapy.
• Understanding γδ T cell subsets (Vδ1, Vδ2) and their manipulation is crucial for optimizing therapy.

Conclusions:

• γδ T cells represent a promising next-generation approach in cancer immunotherapy.
• Further research into γδ T cell activation, exhaustion, and genetic modification can maximize their antitumor potential.
• Targeting γδ T cells offers a viable strategy to overcome limitations in current cancer immunotherapies.